Faculty
Alpesh Amin, M.D., MBA, FACC, MACP, SFHM
Thomas & Mary Cesario Chair of Medicine
Professor of Medicine, Business, Public Health, Nursing Science, and Biomedical Engineering
Executive Director, Hospitalist Program
Medical Director, Anticoagulation Services
University of California, Irvine
Irvine, California
Alpesh Amin, M.D., MBA, FACC, MACP, SFHM, is the Thomas & Mary Cesario Chair of the Department of Medicine at the University of California, Irvine (UCI). He is Professor of Medicine, Business, Public Health, Nursing Science, and Biomedical Engineering at UCI. He is also founder and executive director of the Hospitalist Program. At UCI, Dr. Amin has served as Vice Chair for Clinical Affairs and Quality, Chief of the Division of General Internal Medicine (GIM), Associate Program Director of the Internal Medicine Residency Program, and Medicine Clerkship Director. Dr. Amin obtained his Doctor of Medicine degree at Northwestern University Medical School in Chicago, and he completed his internship and residencies in internal medicine, including a chief residency, at UCI. He also earned a healthcare MBA degree at UCI. Dr. Amin is the first hospitalist to be named chief of a division of GIM, and then subsequently the first hospitalist to be named chair of a department of medicine nationally.
Throughout his career, Dr. Amin has been innovative in clinical, quality, and educational program development. He has advised the Hamad Medical Corporation (HMC) in Doha, Qatar on quality improvement efforts across eight hospitals under the national health ministry council. He has developed processes to improve patient care delivery looking at ways to reduce readmission and avoidable admissions, decrease length of stay and mortality, and improve customer service. Dr. Amin is an expert in implementation science and measuring outcomes to improve sustainable results. He has also applied information technology to improve the delivery of care through development of projects such as NHCPlus, eConsults, and Apps for Safe Anticoagulation Use.
During the course of his career, Dr. Amin has served as principal investigator, co-investigator, and faculty sponsor on clinical trials and research projects focusing on clinical topics, such as venous thromboembolism, pneumonia, and heart failure. His research interest is in health outcomes related to patient safety, quality improvement, and medical education. He is a member of Society of Hospital Medicine (SHM), American College of Physicians (ACP), Society of General Internal Medicine, Academic Chiefs and Leaders of General Internal Medicine (ACLGIM), Academic Alliance of Internal Medicine, and Association of Professors of Medicine. Within SHM, he has served as the Annual Meeting Course Director and on the Board of Directors. Dr. Amin has authored or co-authored over 170 peer-reviewed articles. He is the co-editor and co-author of Core Competencies for Hospital Medicine by SHM. Dr. Amin is also co-editor of the book, Contemporary Hospitalist Guide to Anticoagulation.
Dr. Amin has been honored by being named a Master of ACP, Senior Fellow of SHM, and Fellow of American College of Cardiology. He also has been awarded the ACP Special Recognition Award, ACP Top 10 Hospitalist Award, Orange County Physician of Excellence Award, and he was named one of “America’s Top Physicians” by the Consumers’ Research Council of America. In addition, he received the Alfred Soffer Award from ACCP, Venous Research Award for Quality Improvement and Implementation of Best Practices from the Venous Disease Coalition (VDC)/Vascular Disease Foundation (VDF), Exceptional Leadership Award from ACLGIM, CDC Healthcare-associated VTE Prevention Champion, and HMC Star of Excellence Award. He founded and directs the UCI Anticoagulation Clinic, which is recognized nationally as an AC Forum Center of Excellence.
Adam C. Cuker, M.D., M.S.
Assistant Professor of Medicine and Pathology & Laboratory Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
Adam C. Cuker, M.D., M.S., is Assistant Professor of Medicine and of Pathology and Laboratory Medicine at the University of Pennsylvania Perelman School of Medicine in Philadelphia. He also serves as Director of the Penn Comprehensive Hemophilia and Thrombosis Program and Associate Director of the Penn-CHOP Blood Center for Patient Care and Discovery.
Dr. Cuker received his Doctor of Medicine degree from Yale University in New Haven and completed an internship and residency in internal medicine at Brigham and Women’s Hospital and Harvard Medical School in Boston. He continued his postgraduate training as a fellow in hematology/oncology at the Hospital of the University of Pennsylvania. Dr. Cuker also holds a Master of Science in Translational Research degree from the University of Pennsylvania. He is board certified in internal medicine and hematology and is a fellow of the American College of Physicians.
Dr. Cuker conducts patient-oriented research on heparin-induced thrombocytopenia, venous thromboembolism, and anticoagulation funded by the National Institutes of Health. He is Chair of the forthcoming American Society of Hematology (ASH) guidelines on venous thromboembolism and Chair of the ASH panel on heparin-induced thrombocytopenia.
Paul P. Dobesh, Pharm.D., BCPS-AQ Cardiology, FCCP
Professor of Pharmacy Practice
College of Pharmacy
University of Nebraska Medical Center
Omaha, Nebraska
Paul P. Dobesh, Pharm.D., BCPS-AQ Cardiology, FCCP, is Professor of Pharmacy Practice at the University of Nebraska Medical Center (UNMC) College of Pharmacy in Omaha, Nebraska.
Dr. Dobesh earned both his Bachelor of Science in pharmacy and Doctor of Pharmacy degrees from South Dakota State University. He completed a specialty residency in internal medicine at the University of Texas at Austin at Brackenridge Hospital. He is a board-certified pharmacotherapy specialist with added qualifications in cardiology.
Dr. Dobesh currently maintains clinical practice with cardiology services at Nebraska Medical Center. He is responsible for teaching pharmacy and medical students, as well as pharmacy and medical residents. His main lecture topics include ischemic heart disease, antithrombotic therapy, and other cardiology and critical care topics. Dr. Dobesh has conducted research on antiplatelet and antithrombotic therapy, focusing on the real-world use of these therapies and healthcare economics. He has also published book chapters and several manuscripts in this area.
Dr. Dobesh was awarded the Distinguished Educator of the Year Award at the UNMC College of Pharmacy in 2015, an award he received four times since 2007. In 2013, he was honored with the UNMC campuswide Outstanding Educator Award.
John Fanikos, R.Ph., MBA
Executive Director of Pharmacy Services
Brigham and Women’s Hospital
Adjunct Professor of Clinical Pharmacy
Massachusetts College of Pharmacy and Health Sciences
Boston, Massachusetts
John Fanikos, R.Ph., M.B.A., is Chief of Pharmacy Services at Brigham and Women's Hospital (BWH) in Boston, Massachusetts. Mr. Fanikos is responsible for the overall Pharmacy Department operations. As part of his research interests, he has worked closely with the BWH Thromboembolism Research Group for over 25 years. He has authored and co-authored over 100 peer reviewed articles and textbook chapters on medication use with a specific emphasis on optimizing medication utilization. His research focus has been identifying and avoiding the problems and pitfalls of medication use.
Relevant Financial Relationship Disclosure with an Ineligible Company*
- Consultant, Pfizer
- Consultant, Pacira
- Consultant, Boehringer-Ingelheim
- Consultant, Allergan
- Consultant, Alexion
All of the relevant financial relationships have been mitigated.
*As defined by the Standards of Integrity and Independence definition of ineligible company.
Rachel P. Rosovsky, M.D., M.P.H.
Assistant Physician
Department of Hematology/Oncology
Massachusetts General Hospital
Instructor in Medicine
Harvard Medical School
Boston, Massachusetts
Rachel P. Rosovsky, M.D., M.P.H., is an assistant physician in the Department of Hematology/Oncology at Massachusetts General Hospital (MGH) in Boston and an instructor in medicine at Harvard Medical School (HMS).
Dr. Rosovsky earned her undergraduate degree from the University of Pennsylvania, Doctor of Medicine degree from Harvard Medical School, and Master in Public Health degree from Harvard School of Public Health. She completed her residency at Brigham and Women’s Hospital and fellowship at the Dana Farber Cancer Institute, both in Boston. She is board certified in hematology and medical oncology. She is an expert and leader in the field of venous thromboembolism (VTE), and her clinical and research interest and expertise revolve around the evaluation and treatment of patients with this condition.
Dr. Rosovsky is on the Board of Directors of the National Pulmonary Embolism Response Team (PERT) Consortium, and she is Chair of the Consortium’s Education Committee. She recently helped establish a national educational series for PERT members to discuss the most up-to-date topics and controversies in the work up and treatment of VTE, as well as a monthly newsletter highlighting current evidence-based literature on VTE. Dr. Rosovsky also serves on the Executive Committee of the MGH PERT and is the creator and director of the MGH PERT multidisciplinary follow-up clinic, the goals of which are to improve the care of patients with pulmonary embolism as they transition from inpatient to outpatient setting, standardize follow-up protocols, increase patient satisfaction, and expand patient education.
Dr. Rosovsky is actively engaged in the education of medical students, residents and fellows. In addition to bedside teaching and supervision during outpatient clinics and inpatient rotations, she lectures at continuing medical education courses locally, nationally and internationally. Dr. Rosovsky is also actively involved in research, investigating the risks, diagnosis, and treatment of VTE and other benign hematological conditions. Past research includes an analysis of endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide and dexamethasone and a study of VTE risk in cancer patients with increased tissue factor particles who are treated with a low molecular weight heparin (LMWH). Currently, she is participating in an international study comparing a LMWH product with one of the new direct oral anticoagulants (DOACs) in cancer patients with acute VTE. She is also the co-principal investigator on a multicenter study investigating the safety and efficacy of treating low risk deep vein thrombosis and pulmonary embolism (PE) in an outpatient setting, and she is the national lead investigator for an evaluation of a DOAC for low risk PE patients. She is involved in creating a PERT registry and national database to assess current treatments and long-term outcomes in patients with VTE. Through lectures, research, and written works that include original articles, book chapters, and scholarly reviews, she seeks to improve the care of patients with VTE and advance the understanding and treatment of this medical condition.
Toby C. Trujillo, Pharm.D., BCPS-AQ Cardiology, FAHA, FCCP, Initiative Chair
Associate Professor
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Clinical Specialist - Anticoagulation/Cardiology
University of Colorado Hospital
Aurora, Colorado
Toby C. Trujillo, Pharm.D., BCPS-AQ Cardiology, FAHA, FCCP, is Associate Professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences in Aurora. He also is a clinical specialist in anticoagulation and cardiology at University of Colorado Hospital.
Dr. Trujillo earned his Bachelor of Science degree in biochemistry from the University of California, Davis and his Doctor of Pharmacy degree from the University of California, San Francisco, where he also completed a residency in pharmacy practice. He then went on to do a fellowship in cardiovascular pharmacotherapy at The University of Arizona. Dr. Trujillo is a board-certified pharmacotherapy specialist with added qualifications in cardiology.
In his current role, Dr. Trujillo is involved in the stewardship of antithrombotic medications across the UC Health system, which includes serving as co-chair of the anticoagulation subcommittee of the P&T committee, as well as coordinating and staffing the Inpatient Anticoagulation Thrombosis Management Service.
Dr. Trujillo has served in several capacities within multidisciplinary healthcare organizations, such as the American Heart Association, American College of Cardiology, and Society of Critical Care Medicine. He has also served on committees and in leadership positions within the American College of Clinical Pharmacy, currently as a member of the ACCP Board of Regents. Dr. Trujillo is often invited to speak on a national level, and he authored several articles and book chapters in the area of cardiovascular pharmacotherapy.
